Accepted Manuscript

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

Zheng-Hai Tang, Jin-Jian Lu

PII: S0304-3835(18)30129-0

DOI: 10.1016/j.canlet.2018.02.004

Reference: CAN 13754

To appear in: Cancer Letters

Received Date: 1 December 2017
Revised Date: 1 February 2018
Accepted Date: 2 February 2018

Please cite this article as: Z.-H. Tang, J.-J. Lu, Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.02.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies

Zheng-Hai Tang, Jin-Jian Lu*

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

*Correspondence author: Dr. Jin-Jian Lu, 7014, N22, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macao. Email address: jinjianlu@umac.mo; jinjian.lu@163.com. Phone number: 853-88224674. Fax number: 853-28841358

Download English Version:

https://daneshyari.com/en/article/8434623

Download Persian Version:

https://daneshyari.com/article/8434623

<u>Daneshyari.com</u>